Privately-held ConcertAI has formally integrated with TeraRecon, a provider of advanced visualization services, including 3D and 4D medical imaging post-processing.
Cambridge, Massachusetts–based ConcertAI says the integration will expand its offerings for life science companies, which now can integrate data from electronic medical records, genomic data and medical imaging. As a result, the company can offer software-as-a-service (SaaS) clinical research and clinical decision support applications.
“For oncology studies, imaging is a critical part of both patient care and defining response to therapy,” said Kenneth G. Faulkner, SVP of clinical trial solutions at ConcertAI. In 2018, the FDA released guidance on the use of imaging in clinical trials highlighting the need for standardized procedures to “reduce variability and to ensure interpretability of the results.”
Kenneth G. Faulkner
“While the clinical use of imaging is somewhat standardized for patient care, clinical studies — particularly in oncology — require trial-specific standards for accurate endpoint determination,” Faulkner said.
TeraRecon is currently in use in 1,300 clinical sites internationally.
TeraRecon is a segment winner in advanced visualization, according to KLAS Research, a market research firm.
ConcertAI plans on integrating TeraRecon’s technologies into its Digital Clinical Trials Network.
“TeraRecon provides the necessary analytic tools and procedures for standardizing imaging endpoints in oncology,” Faulkner said. “By deploying TeraRecon tools into ConcertAI workflows, we can better control standardized workflows and assessments within the clinical trial setting — leading to more accurate assessments of disease progression and treatment efficacy.”
In 2021, ConcertAI has announced a string of collaborations related to pharmaceutical clinical trials, including an expanded data science partnership with Janssen (NYSE:JNJ), Novartis (NYSE:NVS) and Syneos Health (NSDQ:SYNH).
Filed Under: clinical trials, Drug Discovery, Oncology
